Altimmune Sees Unusually Large Options Volume (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) was the target of unusually large options trading activity on Monday. Stock investors bought 15,499 call options on the company. This is an increase of 78% compared to the typical daily volume of 8,714 call options.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently bought and sold shares of the company. Timelo Investment Management Inc. increased its stake in Altimmune by 2,597.0% during the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after buying an additional 779,095 shares during the period. Knoll Capital Management LLC boosted its holdings in shares of Altimmune by 183.6% in the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after buying an additional 367,219 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Altimmune by 1,282.4% in the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after buying an additional 436,000 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Altimmune by 153.1% during the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after purchasing an additional 269,676 shares during the period. Finally, Lighthouse Investment Partners LLC acquired a new stake in Altimmune during the 4th quarter worth $4,493,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Trading Up 3.8 %

ALT opened at $7.41 on Wednesday. The firm has a market capitalization of $525.37 million, a PE ratio of -4.66 and a beta of 0.11. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84. The firm’s 50-day moving average price is $7.11 and its 200 day moving average price is $8.80.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. As a group, analysts predict that Altimmune will post -1.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. JMP Securities cut their price objective on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of Altimmune in a report on Friday, June 21st. B. Riley reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Tuesday, May 14th. Finally, Guggenheim cut shares of Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Altimmune currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.80.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.